CAR T treatment for relapsed CD30-positive T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a lab-made immune therapy (CAR T cells) for lymphoma that has come back or did not respond to treatment, specifically CD30-positive T-cell lymphoma. The goal is to shrink the cancer and help keep it under control after previous therapies, including people who have relapsed after stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and sign consent paperwork for the study
- Have CD30-positive peripheral T-cell lymphoma confirmed by a pathology test (from tissue that shows CD30)
- Have had at least one or two prior treatment “lines,” depending on whether your lymphoma is refractory or relapsed, and it must meet the trial’s timing rules
- Be well enough to safely undergo cell collection and treatment (life expectancy about 6 weeks or more, and blood/organ tests within required ranges)
- Not be pregnant or breastfeeding; if you can become pregnant, you must have recent negative pregnancy tests and use reliable birth control during the study
- Have no active serious infections (like HIV or hepatitis B/C) and be able to follow all study visits and tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy that targets two proteins (CD20 and CD30) on lymphoma cells. It is for people whose lymphoma has come back or not responded to other treatments, including previous stem cell transplants. The goal is to see if this treatment is safe and helps shrink or control the lymphoma.
This trial tests a lab-made immune cell therapy (CAR T) that targets CD30 on certain lymphoma cells. It may help people whose Hodgkin or non-Hodgkin lymphoma has come back or did not respond to usual treatments, including transplant and other medicines.
This trial tests a new type of CAR-T cell therapy that targets both CD20 and CD30 proteins on lymphoma cells. It is for people whose lymphoma has returned or not responded after multiple treatments, including stem cell transplant.
This study tests a new type of therapy called CAR T-cells for people with blood cancers that have returned or not responded to standard treatments. CAR T-cells are made from your own immune cells and are trained to find and kill cancer cells.
This Phase 1 trial tests a new immune therapy made from your own immune cells (CAR T cells) for relapsed or refractory Hodgkin or non-Hodgkin lymphoma that has CD30 on the tumor. It aims to see if the treatment can shrink the lymphoma and find the safest dose.
This trial tests a new type of immunotherapy called CD30 CAR-T cells for people with CD30-positive lymphoma that has come back or hasn't responded to other treatments. The treatment uses your own immune cells that are specially trained to find and kill lymphoma cells carrying the CD30 marker.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.